AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01528735
Drug: BI 201335 NA
RxNorm normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose
Trial: NCT00591760
Drug: Somatotropin
RxNorm normalized name: Somatotropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
Trial: NCT00860262
Drug: amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
Trial: NCT00860262
Drug: telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telmisartan 80mg for the 8w, no titration required
Trial: NCT00860262
Drug: telmisartan and amlodipine
RxNorm normalized name: telmisartan and amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
Trial: NCT00757172
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00757172
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01971554
Drug: MK-8666
RxNorm normalized name: MK-8666
DrugBank: MK-8666 (DB14937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8666, capsules, oral, QD, Days 1 to 14
Trial: NCT02117141
Drug: HC-ER 20 mg capsule (fasted)
RxNorm normalized name: Casporyn HC
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
Trial: NCT02117141
Drug: HC-ER 20 mg capsule (fed)
RxNorm normalized name: Casporyn HC
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
Trial: NCT01102660
Drug: PH-797804
RxNorm normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 6 mg once daily for 2 weeks
Trial: NCT01097304
Drug: Ursodiol
RxNorm normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02571257
Drug: Gemcabene
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-300 mg tablet, QD, 56 days
Trial: NCT02571257
Drug: Gemcabene
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-300 mg tablets, QD, 56 days
Trial: NCT00608634
Drug: perillyl alcohol
RxNorm normalized name: Perillyl alcohol
DrugBank: Perillyl alcohol (DB15289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied as topical cream
Trial: NCT01597349
Drug: FP01
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
Trial: NCT00494013
Drug: Insulin Lispro Protamine Suspension
RxNorm normalized name: Insulin Lispro Protamine Suspension and Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
Trial: NCT00494013
Drug: Detemir
RxNorm normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
Trial: NCT01918813
Drug: vancomycin, mupirocin ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
Trial: NCT01568203
Drug: AMG 579
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
Trial: NCT00905398
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg, Oral, Bid, Daily for three years
Trial: NCT02641873
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
Trial: NCT02641873
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
Trial: NCT02641873
Drug: Levofolinate
RxNorm normalized name: sodium levofolinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
Trial: NCT02641873
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
Trial: NCT00526136
Drug: Vernakalant (oral)
DrugBank: Vernakalant (DB06217)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
Trial: NCT02337322
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02337322
Drug: Darunavir/r
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00760981
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
Trial: NCT01311700
Drug: Injectable (i.v.) metoprolol tartrate (up to 15 mg).
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).~Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.~Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.~Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion.
Trial: NCT02614196
Drug: Galcanezumab
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT02489864
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03704688
Drug: Trametinib 0.5 mg
RxNorm normalized name: trametinib 0.5 MG
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5mg PO q daily
Trial: NCT03704688
Drug: Trametinib 1 MG
RxNorm normalized name: trametinib 1 MG
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.0 mg PO q daily
Trial: NCT03704688
Drug: Trametinib 1.5 MG
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5mg PO q daily
Trial: NCT00718224
Drug: Semuloparin sodium
RxNorm normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection
Trial: NCT00718224
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection
Trial: NCT01277640
Drug: dapivirine
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * dosage form: gel 0.05%~* dosage: 2.5g~* frequency: once daily~* duration: 7 days
Trial: NCT02629159
Drug: Placebo for Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by subcutaneous injection once every other week
Trial: NCT02629159
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by subcutaneous injection once every other week
Trial: NCT02629159
Drug: Placebo for Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets taken orally once a day
Trial: NCT02629159
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets taken orally once a day
Trial: NCT02128178
Drug: Enoxaparin 40 mg 2 hours before arm
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg 2 hours before surgery
Trial: NCT03132181
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
Trial: NCT03790163
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
Trial: NCT00642811
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
Trial: NCT00642811
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
Trial: NCT00642811
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
Trial: NCT02128178
Drug: Enoxaparin 40 mg 12 hours before arm
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg 12 hours before surgery
Trial: NCT01773785
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
Trial: NCT03704688
Drug: Trametinib 2 mg
RxNorm normalized name: trametinib 2 MG
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg PO q daily
Trial: NCT03704688
Drug: Ponatinib 15 MG
RxNorm normalized name: PONATinib 15 MG
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg PO q daily
Trial: NCT03704688
Drug: Ponatinib 30 MG
RxNorm normalized name: PONATinib 30 MG
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg PO q daily
Trial: NCT00002909
Drug: oral sodium phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02135302
Drug: eravacycline
RxNorm normalized name: Eravacycline
DrugBank: Eravacycline (DB12329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
Trial: NCT02373215
Drug: Nalbuphine HCL ER
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine HCL extended release tablet
Trial: NCT00909051
Drug: Acarbose (Glucobay, BAYG5421)
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with diabetes type 2 newly treated with Glucobay
Trial: NCT03697629
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6.
Trial: NCT01112241
Drug: albuterol plus tiotropium
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
Trial: NCT04557280
Drug: Selatogrel
RxNorm normalized name: Selatogrel
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single subcutaneous injection of 16 mg.
Trial: NCT03685409
Drug: Metformin Hydrochloride 500 MG
RxNorm normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride tablets 500 mg given orally once daily.
Trial: NCT00535925
Drug: irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die
Trial: NCT00535925
Drug: ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die
Trial: NCT00535925
Drug: hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)
Trial: NCT03095781
Drug: XL888
RxNorm normalized name: XL888
DrugBank: XL-888 (DB12981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00681486
Drug: Ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
Trial: NCT00681486
Drug: Ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
Trial: NCT00535925
Drug: furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)
Trial: NCT02396888
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of the wound surface was treated daily with 10 units of intermediate insulin.
Trial: NCT00913276
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913276
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02520076
Drug: Alpha-1 Antitrypsin
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Trypsin (DB11237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~* Pre-transplant Day -1~* Post-transplant Day 3~* Post-transplant Day 7~* Post-transplant Day 14
Trial: NCT00535925
Drug: amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension~- Step 3: amlodipine up to 10 mg/die
Trial: NCT00535925
Drug: atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension~- Step 4: atenolol up to 100 mg/die
Trial: NCT00535925
Drug: doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension~- Step 5: doxazosin up to 4 mg/die
Trial: NCT00535925
Drug: clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension~- Step 6: clonidine
Trial: NCT00535925
Drug: insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for Hyperglycaemia (to achieve HbA1c \<7):~- insulin
Trial: NCT00504062
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00535925
Drug: fibrate
RxNorm normalized name: Fibrates
DrugBank: Clofibrate (DB00636)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy for hypertriglyceridemia~- for reducing triglycerides \< 150 mg/dl and/or increasing HDL cholesterol \> 40-50 mg/dl: a fibrate
Trial: NCT00535925
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of anaemia:~- erythropoietin
Trial: NCT00535925
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (in all patients without contraindications):~- aspirin up to 160 mg/die
Trial: NCT01614093
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose intranasal oxytocin (24 IU)
Trial: NCT00504062
Drug: fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00481169
Drug: Bazedoxifene Acetate (TSE-424)
RxNorm normalized name: Bazedoxifene Acetate
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04097444
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02747030
Drug: Ocriplasmin intravenously
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Retinal vein cannulation with Ocriplasmin infusion
Trial: NCT00023387
Drug: Rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00023387
Drug: 25-desacetyl Rifapentine
RxNorm normalized name: 25-DESACETYL RIFAPENTINE
DrugBank: 25-desacetylrifapentine (DB15213)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04097444
Drug: Irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04097444
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00023387
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02985749
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
Trial: NCT03064867
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days
Trial: NCT03064867
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days
Trial: NCT03064867
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle